



MedStar Family Choice

Hepatitis C Therapy - Important Guideline Updates

On December 1, 2018, the Maryland Department of Health is implementing changes to the hepatitis C treatment guidelines for Maryland Medicaid recipients. MedStar Family Choice follows these guidelines. Below is a summary of the changes:

- Fibrosis requirements have been lifted for patients with “a viral condition which is known (documented) to result in an accelerated hepatic disease (fibrosis) progression and /or hepatic decompensation than what is normally expected from the course of chronic HCV.” For example, members with HIV or hepatitis B do not have fibrosis requirements; they can be Metavir F0, F1, F1-2, etc. and qualify for treatment.
- If HIV positive, a viral load that is less than 6 months old must be submitted with the Prior Authorization request.
- If hepatitis B positive, a viral load that is less than 6 months old must be submitted with the Prior Authorization request.
- The following medications will no longer be approved:
 - Viekira (paritaprevir/ritonavir/ombitasvir plus dasabuvir)
 - Technivie (ombitasvir/paritaprevir/ritonavir)
 - Olysio (simeprevir)

Please contact MedStar Family Choice at 800-905-1722, option 2 for Prior Authorization of hepatitis C therapy. Should you have any questions or concerns, please call Dr. Danielle Gerry at 410-933-2295.